Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Two-month angioscopic evaluation of superficial femoral artery treated with paclitaxel-coated nitinol drug-eluting stent.

Ishihara T, Iida O, Awata M, Fujita M, Watanabe T, Ishida Y, Nanto S, Uematsu M.

Circ J. 2013;77(7):1880-2. Epub 2013 Mar 29. No abstract available.

2.

Angioscopically apparent large thrombus and uncovered stent struts 6 months after late stent thrombosis of a paclitaxel-coated nitinol drug-eluting stent implanted in the superficial femoral artery.

Ishihara T, Iida O, Awata M, Shiraki T, Nanto S, Uematsu M.

Cardiovasc Interv Ther. 2014 Jan;29(1):82-5. doi: 10.1007/s12928-013-0197-5. Epub 2013 Jul 10.

PMID:
23839329
3.
4.

Extensive arterial repair one year after paclitaxel-coated nitinol drug-eluting stent vs. bare-metal stent implantation in the superficial femoral artery.

Ishihara T, Iida O, Awata M, Nanto K, Shiraki T, Okamoto S, Iida T, Fujita M, Watanabe T, Nanto S, Uematsu M.

Cardiovasc Interv Ther. 2015 Jan;30(1):51-6. doi: 10.1007/s12928-014-0287-z. Epub 2014 Aug 2.

PMID:
25085265
5.

Effect of bare-metal nitinol stent implantation and paclitaxel-eluting nitinol stent implantation on vascular response in the superficial femoral artery lesion assessed on intravascular ultrasound.

Miki K, Fujii K, Kawasaki D, Fukunaga M, Nishimura M, Horimatsu T, Saita T, Tamaru H, Imanaka T, Shibuya M, Masutani M, Ohyanagi M, Masuyama T.

Circ J. 2014;78(6):1451-8. Epub 2014 Apr 9.

6.

Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.

McQuade K, Gable D, Pearl G, Theune B, Black S.

J Vasc Surg. 2010 Sep;52(3):584-90; discussion 590-1, 591.e1-591.e7. doi: 10.1016/j.jvs.2010.03.071.

7.

Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.

Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T; Zilver PTX Single-Arm Study Investigators.

J Endovasc Ther. 2011 Oct;18(5):613-23. doi: 10.1583/11-3560.1.

PMID:
21992630
8.

Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.

Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM; VIBRANT Investigators.

J Vasc Surg. 2013 Aug;58(2):386-95.e4. doi: 10.1016/j.jvs.2013.01.050. Epub 2013 May 13.

9.

Vascular response after Zilver PTX stent implantation for superficial femoral artery lesions: serial optical coherence tomography findings at 6 and 12 months.

Tomoi Y, Kuramitsu S, Soga Y, Aihara H, Ando K, Nobuyoshi M.

J Endovasc Ther. 2015 Feb;22(1):41-7. doi: 10.1177/1526602814566577.

PMID:
25775679
10.

Paclitaxel-eluting vs. bare metal stent implantation in saphenous vein graft lesions: Very long-term follow-up of the SOS (Stenting of Saphenous vein grafts) trial.

Sosa A, Chao H, Guerra A, Han H, Christopoulos G, Christakopoulos GE, Tarar MN, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Banerjee S, Brilakis ES.

Int J Cardiol. 2015;186:261-3. doi: 10.1016/j.ijcard.2015.03.267. Epub 2015 Mar 20. No abstract available.

PMID:
25828130
11.

drug-eluting nitinol stent treatment of the superficial femoral artery and above-the-knee popliteal artery (the Zilver PTX single-arm clinical study): a comparison between diabetic and nondiabetic patients.

Fanelli F, Di Primo M, Boatta E, Johnston K, Sapoval M.

Cardiovasc Intervent Radiol. 2013 Oct;36(5):1232-40. doi: 10.1007/s00270-012-0543-5. Epub 2013 Jan 9.

PMID:
23299704
12.

Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.

Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Snyder SA, O'Leary EE, Tepe G, Scheinert D, Zeller T; Zilver PTX Investigators.

J Am Coll Cardiol. 2013 Jun 18;61(24):2417-27. doi: 10.1016/j.jacc.2013.03.034. Epub 2013 Apr 10. Erratum in: J Am Coll Cardiol. 2013 Aug 13;62(7):666.

13.

Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial.

Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR; RESILIENT Investigators.

Circ Cardiovasc Interv. 2010 Jun 1;3(3):267-76. doi: 10.1161/CIRCINTERVENTIONS.109.903468. Epub 2010 May 18.

14.

Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up.

Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y.

Clin Cardiol. 2011 May;34(5):322-6. doi: 10.1002/clc.20881. Epub 2011 Mar 22.

15.

Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).

Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tübler T, Zeller T.

Circulation. 2007 Jul 17;116(3):285-92. Epub 2007 Jun 25.

16.

Treatment of coronary drug-eluting stent restenosis: a journey back to the future?

King LA, Kastrati A, Byrne RA.

Expert Rev Med Devices. 2013 Jul;10(4):423-7. doi: 10.1586/17434440.2013.811830. Review. No abstract available.

PMID:
23895067
17.

Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.

McQuade K, Gable D, Hohman S, Pearl G, Theune B.

J Vasc Surg. 2009 Jan;49(1):109-15, 116.e1-9; discussion 116. doi: 10.1016/j.jvs.2008.08.041. Epub 2008 Nov 22.

18.

Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results.

Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi JP.

Circulation. 2002 Sep 17;106(12):1505-9.

19.

Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.

Katsanos K, Spiliopoulos S, Karunanithy N, Krokidis M, Sabharwal T, Taylor P.

J Vasc Surg. 2014 Apr;59(4):1123-1133.e8. doi: 10.1016/j.jvs.2014.01.041. Review.

20.

Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).

Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristl R, Schoder M.

J Am Coll Cardiol. 2013 Oct 8;62(15):1320-7. doi: 10.1016/j.jacc.2013.05.079. Epub 2013 Jul 10.

Supplemental Content

Support Center